You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理升康方生物(09926.HK)目標價至56元 cadonilimab銷售強勁
阿思達克 03-21 10:14
麥格理發表研究報告指,康方生物(09926.HK)研發的卡度尼利單抗(cadonilimab)銷售非常強勁,抵銷了公司另一款藥物PD-1 penpulimab銷售額按年下降51%的影響。該行同時指cadonilimab (PD-1/CTLA-4)於進入市場後,第二年的銷售額強勁,按年上升約1.4倍,並超出公司銷售指引的12億元人民幣(同下)至13億元。因此該行對公司2024年及2025年的銷售額預測維持不變,並符合2024年「穩定成長」的銷售指引。 另外,該行指出康方生物於2023年錄得盈利,主要得益於一次性合夥支付。該行預期公司將從2026年開始持續獲利,並預計可以於2025年在A股市場上市。因此麥格理將康方生物的目標價上調14%至56港元,評級「跑贏大市」。(js/w) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account